title: Pharmacokinetics of biologics and the role of therapeutic monitoring.
abstract: Biologic therapies, including the anti-tumor necrosis factor-α and cell adhesion molecule inhibitor drugs, have revolutionized the treatment of moderate-to-severe inflammatory bowel disease. Since the introduction of anti-tumor necrosis factor therapies, the strategy of empiric dose-escalation, either increasing the dose or frequency of administration, has been used to recapture clinical response in inflammatory bowel disease. Disparate clinical outcomes have been linked to serum drug and antidrug antibody levels. Therapeutic drug monitoring has emerged as a framework for understanding and responding to the variability in clinical response and remission.
authors.affiliation: UCSF Center for Colitis and Crohn's Disease, Division of Gastroenterology, Department of Medicine, University of California, San Francisco, 1701 Divisadero Street, San Francisco, CA 94115, USA.
authors.forename: Kirk
authors.initials: K
authors.lastname: Lin
authors.affiliation: UCSF Center for Colitis and Crohn's Disease, Division of Gastroenterology, Department of Medicine, University of California, San Francisco, 1701 Divisadero Street, San Francisco, CA 94115, USA. Electronic address: uma.mahadevan@ucsf.edu.
authors.forename: Uma
authors.initials: U
authors.lastname: Mahadevan
mesh_terms: D000068879:Adalimumab; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000493:pharmacokinetics*; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics; D061067:Antibodies, Monoclonal, Humanized / Q000493:pharmacokinetics; D001688:Biological Products / Q000493:pharmacokinetics; D000068582:Certolizumab Pegol; D016903:Drug Monitoring / Q000379:methods; D006801:Humans; D007140:Immunoglobulin Fab Fragments; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab; D000069442:Natalizumab; D011092:Polyethylene Glycols / Q000493:pharmacokinetics; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D007140:Immunoglobulin Fab Fragments; D000069442:Natalizumab; D014409:Tumor Necrosis Factor-alpha; D011092:Polyethylene Glycols; C529000:golimumab; D000069285:Infliximab; D000068879:Adalimumab; D000068582:Certolizumab Pegol
keywords: Biologics; Inflammatory bowel disease; Pharmacokinetics; Therapeutic drug monitoring